Description

Simple

Clinical

Overview

Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Farletuzumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Farletuzumab.
Abituzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Farletuzumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Farletuzumab.
Aducanumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Farletuzumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Farletuzumab.
Alirocumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Farletuzumab.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Farletuzumab.
Apolizumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Asfotase alfa.